Clinical Trials Logo
  1. Home
  2. Metastatic Ovarian Cancer
  3. NCT01768156

Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer — Meta-Four  

Metastatic Ovarian Cancer Clinical Trial

Official title:
Determination of the Prognostic and Predictive Value of the New Marker HE4 in Metastatic Ovarian Cancer Monitoring

Clinical Trial Summary

HE4 is a new marker that could improve the detection of ovarian cancer. The HE4 assay may have an advantage over the CA-125 assay in that it is less frequently positive in patients with non malignant disease. Since the evaluation of HE4 for detection and diagnosis of ovarian cancer is well known, the behaviour of the marker during chemotherapy and follow-up period after treatment in metastatic ovarian cancer should be studied. It could be used in patient with non CA-125 secretary tumors. Prognosis and predictive value of HE4 should be compared with information provided by CA-125. The kinetics of HE4 values after treatment should be also analysed to determine the role that HE4 could play in the detection of recurrences during the follow-up of metastatic patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01768156
Study type Interventional
Source Institut du Cancer de Montpellier - Val d'Aurelle
Contact
Status Completed
Phase N/A
Start date September 24, 2010
Completion date November 15, 2016
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT03634150 - Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer Phase 1/Phase 2
Completed NCT03287674 - TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer Phase 1/Phase 2
Recruiting NCT05796973 - Measuring Oncological Value of Exercise and Statin Phase 3
Terminated NCT03277482 - Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Phase 1
Completed NCT02482090 - TIL Therapy for Metastatic Ovarian Cancer Phase 1
Recruiting NCT03150992 - EDMONd - Elemental Diet in Bowel Obstruction N/A
Recruiting NCT03412526 - Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian Phase 2
Recruiting NCT01174121 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Phase 2
Recruiting NCT04611126 - T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Phase 1/Phase 2
Completed NCT03242993 - [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging Phase 1